Coherus Oncology, Inc. has priced an underwritten public offering of 28.6 million shares of common stock at $1.75 per share, generating approximately $50.1 million in gross proceeds. The offering is expected to close on February 17, 2026, subject to customary closing conditions and regulatory approvals.
The biopharmaceutical company intends to deploy the capital toward multiple strategic initiatives, including the commercial expansion of LOQTORZI, its PD-1 inhibitor, and the advancement of clinical development programs across its oncology pipeline. The funds will also support general corporate operations and working capital needs as the company scales its operations.
The offering underscores Coherus Oncology's efforts to strengthen its financial position as it executes on its commercial and development strategy in the competitive oncology therapeutics market.